Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

COVID-19 and Alzheimer's Disease: The Link Finally Established

Author(s): Ziad Fajloun, Yingliang Wu, Zhijian Cao, Hervé Kovacic and Jean-Marc Sabatier*

Volume 23, Issue 7, 2023

Published on: 27 June, 2023

Article ID: e290523217428 Pages: 3

DOI: 10.2174/1871526523666230529162633

Open Access Journals Promotions 2
[1]
El-Arif G, Farhat A, Khazaal S, et al. The renin-angiotensin system: A key role in SARS-CoV-2-induced COVID-19. Molecules 2021; 26(22): 6945.
[http://dx.doi.org/10.3390/molecules26226945] [PMID: 34834033]
[2]
Fajloun Z, Kovacic H, Annweiler C, Wu Y, Cao Z, Sabatier JM. SARS-CoV-2-induced neurological disorders in symptomatic COVID-19 and long COVID patients: key role of brain renin-angiotensin system. Infect Disord Drug Targets 2022; 22(5): e060422203203.
[http://dx.doi.org/10.2174/1871526522666220406124618] [PMID: 35388764]
[3]
Annweiler C, Cao Z, Papon N, Kovacic H, Sabatier JM. Counter-regulatory renin-angiotensin system: An important line of research to un-derstand and limit the severity of COVID-19. Infect Disord Drug Targets 2022; 22(2): e100921196331.
[http://dx.doi.org/10.2174/1871526521666210910063227] [PMID: 34515015]
[4]
El-Arif G, Khazaal S, Farhat A, et al. Angiotensin II Type I receptor (AT1R): The gate towards COVID-19-associated diseases. Molecules 2022; 27(7): 2048.
[http://dx.doi.org/10.3390/molecules27072048] [PMID: 35408447]
[5]
Kumar A, Sidhu J, Goyal A, et al. Alzheimer Disease.StatPearls. Treasure Island, FL: StatPearls Publishing 2023. https://www.ncbi.nlm.nih.gov/ books/NBK499922/ Updated 2022 Jun 5
[6]
Khazaal S, Harb J, Rima M, et al. The pathophysiology of long COVID throughout the renin-angiotensin system. Molecules 2022; 27(9): 2903.
[http://dx.doi.org/10.3390/molecules27092903] [PMID: 35566253]
[7]
Wang L, Davis PB, Volkow ND, Berger NA, Kaelber DC, Xu R. Association of COVID-19 with New-Onset Alzheimer’s Disease. J Alzheimers Dis 2022; 89(2): 411-4.
[http://dx.doi.org/10.3233/JAD-220717] [PMID: 35912749]
[8]
Ozkan S, Adapinar DO, Elmaci NT, Arslantas D. Apraxia for differentiating Alzheimer’s disease from subcortical vascular dementia and mild cognitive impairment. Neuropsychiatr Dis Treat 2013; 9: 947-51.
[http://dx.doi.org/10.2147/NDT.S47879] [PMID: 23882142]
[9]
Pluta R, Ułamek-Kozioł M. Tau protein-targeted therapies in Alzheimer’s disease: Current state and future perspectives. Alzheimer’s disease: Drug discovery. Brisbane (AU): Exon publications 2020. https://www.ncbi.nlm.nih.gov/books/NBK566118/
[http://dx.doi.org/10.36255/exonpublications.alzheimersdisease.2020.ch4]
[10]
Chen F, Chen Y, Wang Y, Ke Q, Cui L. The COVID-19 pandemic and Alzheimer’s disease: Mutual risks and mechanisms. Transl Neurodegener 2022; 11(1): 40.
[http://dx.doi.org/10.1186/s40035-022-00316-y] [PMID: 36089575]
[11]
Rygiel K. Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer’s disease? An overview of research evidence in the elderly patient population. J Postgrad Med 2016; 62(4): 242-8.
[http://dx.doi.org/10.4103/0022-3859.188553] [PMID: 27763482]
[12]
Kaur P, Muthuraman A, Kaur M. The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: Current and future perspectives. ACS Chem Neurosci 2015; 6(4): 508-21.
[http://dx.doi.org/10.1021/cn500363g] [PMID: 25680080]
[13]
Balogun TA, Chukwudozie OS, Ogbodo UC, et al. Discovery of putative inhibitors against main drivers of SARS-CoV-2 infection: Insight from quantum mechanical evaluation and molecular modeling. Front Chem 2022; 10: 964446.
[http://dx.doi.org/10.3389/fchem.2022.964446] [PMID: 36304744]
[14]
Annweiler C, Papon N, Sabatier JM, Barré J. DAMPening Severe COVID-19 with Dexamethasone. Infect Disord Drug Targets 2022; 22(2): e270821195910.
[http://dx.doi.org/10.2174/1871526521999210827142839] [PMID: 34455971]
[15]
Mehraeen E, Najafi Z, Hayati B, et al. Current treatments and therapeutic options for COVID-19 patients: A Systematic review. Infect Disord Drug Targets 2022; 22(1): e260721194968.
[http://dx.doi.org/10.2174/1871526521666210726150435] [PMID: 34313204]
[16]
Annweiler C, Hanotte B, Grandin de l’Eprevier C, Sabatier JM, Lafaie L, Célarier T. Vitamin D and survival in COVID-19 patients: A quasi-experimental study. J Steroid Biochem Mol Biol 2020; 204: 105771.
[http://dx.doi.org/10.1016/j.jsbmb.2020.105771] [PMID: 33065275]
[17]
Cao Z, Wu Y, Faucon E, Sabatier JM. SARS-CoV-2 & Covid-19: Key-roles of the ‘renin-angiotensin’ system/vitamin D impacting drug and vaccine developments. Infect Disord Drug Targets 2020; 20(3): 348-9.
[http://dx.doi.org/10.2174/22123989MTA2nMzg9x] [PMID: 32370727]

Rights & Permissions Print Cite
Article Metrics
37
5
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy